Please assess the completion status of the following clinical trial:

Trial Title: Stress Echocardiography Study With Regadenoson

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress~* Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress~Exclusion Criteria:~* Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography~* Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regadenoson alone (Type: EXPERIMENTAL): None
- Regadenoson with exercise (Type: EXPERIMENTAL): None
- Regadenoson with contrast agent (Type: EXPERIMENTAL): None
- Regadenoson with contrast agent (perfusion) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).